首页 文献索引 SCI期刊 AI助手
首页 正文

Once-Monthly Efimosfermin Alfa for Up to 48 Weeks in MASH With F2/F3 Fibrosis: Results From a Phase 2, Open-Label Extension Study

{{output}}